The risk evaluation and mitigation strategy program for clozapine allows for patients to receive clozapine—even in the setting of moderate to severe neutropenia—if the benefit to psychiatric treatment outweighs the risk of recurrent neutropenia. However, literature that can guide appropriate treatment for such patients is limited. A recently published case report suggests that using filgrastim to control leukopenia and neutropenia could allow patients to continue to receive clozapine without interruption.
For patients with treatment-resistant schizophrenia, clozapine is a key antipsychotic. However, because clozapine is associated with hematological abnormalities, including neutropenia and leukopenia, patients must sometimes discontinue treatment. Sudden withdrawal of clozapine is linked with serious outcomes, however, including an increased risk of suicide.
The risk evaluation and mitigation strategy program for clozapine allows for patients to receive clozapine—even in the setting of moderate to severe neutropenia—if the benefit to psychiatric treatment outweighs the risk of recurrent neutropenia. However, literature that can guide appropriate treatment for such patients is limited.
A recently published case report suggests that using filgrastim to control leukopenia and neutropenia could allow patients to continue to receive clozapine without interruption. Published in The Mental Health Clinician, the report describes a 55-year-old male patient with chronic paranoid schizophrenia.
Learn more about filgrastim biosimilars.
The patient had achieved significant clinical improvement with clozapine treatment, and he attained functional independence without hospitalization. He was able to receive 20 years of clozapine therapy before he developed leukopenia, after which clozapine was withdrawn, precipitating a rapid worsening of his schizophrenia symptoms. Over the following 2 years, the patient tried, and had an inadequate response to, 7 other medications.
Because the patient’s symptoms were worsening, a retrial of clozapine was deemed necessary. However, 2 months after discharge from the hospital following psychiatric improvement with clozapine therapy, moderate leukopenia and mild neutropenia recurred, and his clozapine was once again held.
The patient was then treated with 5 daily doses of subcutaneous filgrastim (300 mcg/mL), and his white blood cells and absolute neutrophil count recovered within 4 days, allowing him to restart his clozapine. An interdisciplinary team determined that the patient could receive uninterrupted clozapine therapy with filgrastim as needed.
The patient had 1 period of leukopenia and neutropenia that necessitated interruption of clozapine, and his filgrastim was eventually replaced with a different colony-stimulating factor therapy (sargramostim) because of a formulary change, but over the past 3 years of receiving neutropenia treatment, his schizophrenia symptoms have been well controlled, and his clozapine use has been uninterrupted. The patient continues to have his white blood cells and absolute neutrophil count monitored weekly.
The authors of the case report conclude that filgrastim or sargramostim provide a potential alternative to clozapine discontinuation in the case of neutropenia for patients who have been clinically stable on their therapy.
Reference
Kars A, Lister J. Utilization of G-CSF and GM-CSF as an alternative to discontinuation in clozapine-induced neutropenia or leukopenia: a case report and discussion. Ment Health Clin. 2018;8(5):250-255. doi: 10.9740/mhc.2018.09.250.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.